The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss—up to 24% with ...

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.